Aller au contenu. | Aller à la navigation

Outils personnels

  • Le CIRI sur Linkedin
Navigation

Tutelles

logo Inserm      logo cnrslogo ENSL       logo ucb1


Tutelles secondaires

logo ENSL logo ucb1

Vous êtes ici : Accueil / Équipes / Doublet P/Jarraud S - LegioPath / Publications

Publications

ALL OUR PUBLICATIONS ARE ON PUBMED

Click here

Selected publications since 2020 (group members are underlined)

 

EFFECTORS and Type IV Secretion in L. pneumophila

Dual Control of Host Actin Polymerization by a Legionella Effector Pair. M. Pillon, C. Michard, N. BaïloJ. Bougnon, K. Picq, O. DuboisC. Andrea, L. Attaiech, V. Daubin, S. JarraudE. KayP. DoubletCell. Microbiol. 2024 vol. 2024 ID 8896219 https://doi.org/10.1155/2024/8896219

Deciphering Legionella effector delivery by Icm/Dot secretion system reveals a new role for c-diGMP signaling. Allombert J, Jaboulay C, Michard C, Andréa C, Charpentier X, Vianney A, Doublet P. J Mol Biol. 2021 Apr 9:166985. doi: 10.1016/j.jmb.2021.166985.PMID: 33845084

Regulatory Networks of the T4SS Control: From Host Cell Sensing to the Biogenesis and the Activity during the Infection. Jaboulay C, Godeux AS, Doublet P, Vianney A. J Mol Biol. 2021 Apr 30;433(9):166892. doi: 10.1016/j.jmb.2021.166892. Epub 2021 Feb 23.PMID: 33636165 Review.

 

Legionellosis treatment failure and antibiotic resistance

Bacterial persistence in Legionella pneumophila clinical isolates from patients with recurring legionellosis. Adams-Ward X, Chapalain A, Ginevra C, Jarraud S, Doublet P, Gilbert C. Front Cell Infect Microbiol2023 Aug 1;13:1219233. doi: 10.3389/fcimb.2023.1219233. eCollection 2023. PMID: 37600942 

Intracellular persister: A stealth agent recalcitrant to antibiotics. Personnic N, Doublet P, Jarraud S. Front Cell Infect Microbiol. 2023 Mar 31;13:1141868. doi: 10.3389/fcimb.2023.1141868. eCollection 2023. PMID: 37065203

Detection of highly macrolide-resistant Legionella pneumophila strains from a hotel water network using systematic whole-genome sequencing. Ginevra C, Beraud L, Pionnier I, Sallabery K, Bentayeb H, Simon B, Allam C, Chastang J, Ibranosyan M, Decroix V, Campese C, Jarraud S, Descours GJ Antimicrob Chemother. 2022 Jul 28;77(8):2167-2170. doi: 10.1093/jac/dkac173. PMID: 35678276

Legionella antibiotic susceptibility testing: is it time for international standardization and evidence-based guidance? Portal E, Descours G, Ginevra C, Mentasti M, Afshar B, Chand M, Day J, Echahidi F, Franzin L, Gaia V, Lück C, Meghraoui A, Moran-Gilad J, Ricci ML, Lina G, Uldum S, Winchell J, Howe R, Bernard K, Spiller OB, Chalker VJ, Jarraud S; ESCMID Study Group for Legionella Infections (ESGLI). J Antimicrob Chemother. 2021 Apr 13;76(5):1113-1116. doi: 10.1093/jac/dkab027.PMID: 33608737

Persistent Legionnaires' Disease and Associated Antibiotic Treatment Engender a Highly Disturbed Pulmonary Microbiome Enriched in Opportunistic Microorganisms. Pérez-Cobas AE, Ginevra C, Rusniok C, Jarraud S, Buchrieser C. mBio. 2020 May 19;11(3):e00889-20. doi: 10.1128/mBio.00889-20.PMID: 32430469 

Slowly or Nonresolving Legionnaires' Disease: Case Series and Literature Review. Pouderoux C, Ginevra C, Descours G, Ranc AG, Beraud L, Boisset S, Magand N, Conrad A, Bergeron-Lafaurie A, Jarraud S, Ader FClin Infect Dis. 2020 Apr 15;70(9):1933-1940. doi: 10.1093/cid/ciz538.PMID: 31242293

 

SEVERITY of legionellosis 

Hyper-inflammatory profile and immunoparalysis in patients with severe Legionnaires' disease. Allam C, Mouton W, Testaert H, Ginevra C, Fessy N, Ibranosyan M, Descours G, Beraud L, Guillemot J, Chapalain A, Albert-Vega C, Richard JC, Argaud L, Friggeri A, Labeye V, Jamilloux Y, Freymond N, Venet F, Lina G, Doublet P, Ader F, Trouillet-Assant S, Jarraud S. Front Cell Infect Microbiol. 2023 Oct 27;13:1252515. doi: 10.3389/fcimb.2023.1252515. eCollection 2023.

The respiratory tract microbiome, the pathogen load, and clinical interventions define severity of bacterial pneumonia Pérez-Cobas AE, Ginevra C, Rusniok C, Jarraud S, Buchrieser C. Cell Rep Med. 2023 Sep 19;4(9):101167. doi: 10.1016/j.xcrm.2023.101167. Epub 2023 Aug 25. PMID: 37633274 

Hiding in the yolk: A unique feature of Legionella pneumophila infection of zebrafish. Viana F, Boucontet L, Laghi V, Schator D, Ibranosyan M, Jarraud S, Colucci-Guyon E, Buchrieser C. PLoS Pathog. 2023 May 8;19(5):e1011375. doi: 10.1371/journal.ppat.1011375. eCollection 2023 May. PMID: 37155695 

TNF-α response in macrophages depends on clinical Legionella pneumophila isolates genotypes.  Guillemot JGinevra CAllam CKay EGilbert CDoublet PJarraud SChapalain AVirulence. 2022 Dec;13(1):160-173. doi: 10.1080/21505594.2021.2022861

 

Epidemiology and clinical microbiology of legionellosis 

Rapid adaptations of Legionella pneumophila to the human host. Leenheer D, Moreno AB, Paranjape K, Murray S, Jarraud S, Ginevra C, Guy L. Microb Genom. 2023 Mar;9(3):mgen000958. doi: 10.1099/mgen.0.000958. PMID: 36947445 

A real-time PCR for specific detection of the Legionella pneumophila serogroup 1 ST1 complex. Ginevra C, Chastang J, David S, Mentasti M, Yakunin E, Chalker VJ, Chalifa-Caspi V, Valinsky L, Jarraud S, Moran-Gilad J; ESCMID Study Group for Legionella Infections (ESGLI). Clin Microbiol Infect. 2020 Apr;26(4):514.e1-514.e6. doi: 10.1016/j.cmi.2019.09.002. Epub 2019 Sep 13.PMID: 31525518

Transmission of Legionnaires'' Disease through Toilet Flushing. Couturier J, Ginevra C, Nesa D, Adam M, Gouot C, Descours G, Campèse C, Battipaglia G, Brissot E, Beraud L, Ranc AG, Jarraud S, Barbut F. Emerg Infect Dis. 2020 Jul;26(7):1526-1528. PMID: 32568063

 

publication related to SarS-Cov2 infection and  severity of COVID-19

COVID-19 diagnosis HCL consortium1. Co-infection with Legionella and SARS-CoV-2, France, March 2020. Allam C, Gaymard A, Descours G, Ginevra C, Josset L, Bouscambert M, Beraud L, Ibranosyan M, Golfier C, Friggeri A, Lina B, Campèse C, Ader F, Jarraud SEmerg Infect Dis. 2021 Sep 1;27(11). doi: 10.3201/eid2711.202150. Epub ahead of print. PMID: 34469708

DisCoVeRy Study Group. Remdesivir plus Standard of Care versus Standard of Care Alone for the Treatment of Patients Admitted to Hospital with COVID-19 (DisCoVeRy): A Phase 3, Randomised, Controlled, Open-Label Trial. Ader, F.; Bouscambert-Duchamp, M.; Hites, M.; Peiffer-Smadja, N.; Poissy, J.; Belhadi, D.; Diallo, A.; Lê, M.-P.; Peytavin, G.; Staub, T.; Greil, R.; Guedj, J.; Paiva, J.-A.; Costagliola, D.; Yazdanpanah, Y.; Burdet, C.; Mentré, F. Lancet Infect. Dis. 2021 Sep 1473-3099(21)00485-0. https://doi.org/10.1016/S1473-3099(21)00485-0